Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Easy Five
- Development stage
- Unknown
- Lead developer
- Panacea Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Easy Five is a liquid pentavalent vaccine developed by Panacea Biotec for the active immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b (Hib). The vaccine is a combination of five components: diphtheria toxoid, tetanus toxoid, inactivated whole-cell Bordetella pertussis, recombinant Hepatitis B surface antigen (HBsAg), and Hib capsular polysaccharide (PRP) conjugated to a tetanus toxoid carrier. It is typically administered as a three-dose primary series in infants starting at six weeks of age. By combining these five antigens into a single injection, Easy Five simplifies the pediatric vaccination schedule, reduces the number of clinic visits, and improves overall immunization coverage and compliance.
- Brand names
- Easy FiveEasyfiveEasyfive-TT
- Other names
- DTP-HepB-Hib vaccinePentavalent vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)PRNP (Cellular Prion Protein)Diphtheria toxin
Beyond the preview
Go deeper on Easy Five.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Easy Five.